Chile: These 4 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Chile Patent 2,004,000,930
Patent Title: COMPUESTO DERIVADO DE DIHIDROQUINAZOLINA DE FORMULA DEFINIDA, UTIL PARA EL TRATAMIENTO Y/O PROFILAXIS DE INFECCIONES VIRALES; COMPOSICION FARMACEUTICA QUE COMPRENDE AL COMPUESTO Y USO DEL COMPUESTO EN LA PREPARACION DE MEDICAMENTOS.

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Chile Patent 2,004,001,119
Patent Title: COMPUESTOS DERIVADOS DE OXIMAS; COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN; Y SU USO COMO INMUNOSUPRESORES UTILES EN ENFERMEDADES MEDIADAS POR EL RECEPTOR EDG, TALEES COMO ENFERMEDADES AUTOINMUNES, INFLAMATORIAS, INFECCIOSAS Y CANCER.

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Chile Patent 2,004,001,120
Patent Title: COMPUESTOS DERIVADOS DE AMINA SUSTITUIDAS CON HETEROCICLOS, INMUNOSUPRESORES; COMPOSICION FARMACEUTICA; Y USO PARA TRATAR ENFERMEDADES MEDIADAS POR INTERACCIONES DE LINFOCITO, TALES COMO ENFERMEDADES AUTOINMUNES, INFLAMATORIAS, INFECCIOSAS, CANCER.

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Chile Patent 2,010,000,775
Patent Title: Compuestos derivados de 3-bencil benceno sustituidos por glucopiranosil; composicion farmaceutica; combinacion farmacuetica que comprende a dichos compuestos; y su uso para el tratamiento o la prevencion de enfermedades metabolicas tales como diabetes, entre otras (divisional de la solicitud 566-05).

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Chile Patent 2,010,000,775
Patent Title: Compuestos derivados de 3-bencil benceno sustituidos por glucopiranosil; composicion farmaceutica; combinacion farmacuetica que comprende a dichos compuestos; y su uso para el tratamiento o la prevencion de enfermedades metabolicas tales como diabetes, entre otras (divisional de la solicitud 566-05).

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.